In this work, we combine the active state selective RAS(ON) G12C-selective compound RMC-4998 with the SHP2 inhibitor RMC-4550 and ICB and investigate the effects of these combinations in preclinical models of lung cancer with varying degrees of immunogenicity. Here, PTPN11 is linked to lung cancer.